News
ENSC
0.2923
-2.86%
-0.0086
Weekly Report: what happened at ENSC last week (0622-0626)?
Weekly Report · 8h ago
Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102
TipRanks · 3d ago
Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection Technology
Benzinga · 3d ago
Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial
PUBT · 3d ago
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Barchart · 3d ago
Weekly Report: what happened at ENSC last week (0615-0619)?
Weekly Report · 06/22 10:40
Weekly Report: what happened at ENSC last week (0608-0612)?
Weekly Report · 06/15 10:40
Weekly Report: what happened at ENSC last week (0601-0605)?
Weekly Report · 06/08 10:35
Ensysce Biosciences files to sell 1.3M shares of common stock for holders
TipRanks · 06/04 20:45
Weekly Report: what happened at ENSC last week (0525-0529)?
Weekly Report · 06/01 10:41
Weekly Report: what happened at ENSC last week (0518-0522)?
Weekly Report · 05/25 10:45
Ensysce Biosciences faces Nasdaq delisting risk over $2.5 million equity shortfall
PUBT · 05/22 20:55
Ensysce Biosciences Has Been Granted European Patent Number EP3934635 Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF (FOR THE TREATMENT OR PREVENTION OF ATTENTION DEFICIT DISORDER (ADHD))"
Benzinga · 05/20 19:59
Ensyce Reports Extension Of Patent On MPAR To Prevent Opioid Abuse
NASDAQ · 05/19 11:22
Ensysce Biosciences posts investor presentation on trypsin-controlled opioids with abuse, overdose protection
PUBT · 05/18 18:13
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45/Share Price Valuation
Benzinga · 05/18 15:05
Weekly Report: what happened at ENSC last week (0511-0515)?
Weekly Report · 05/18 10:45
ENSYSCE BIOSCIENCES INC - LAUNCHES FORMAL REVIEW OF STRATEGIC ALTERNATIVES - SEC FILING
Reuters · 05/15 20:48
Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21
Seeking Alpha · 05/15 20:39
Ensysce Biosciences Q1 net loss widens, cash falls sharply
Reuters · 05/15 20:32
More
Webull provides a variety of real-time ENSC stock news. You can receive the latest news about Ensysce Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About ENSC
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.